Sign in5 stories
At its September 24, 2026 annual meeting, Cadrenal Therapeutics investors approved a larger equity incentive pool and cleared the way for exercise of warrants tied to a July private placement.
SEC filing
After a Type D meeting on July 28, 2026, the FDA and Cadrenal agreed on the primary endpoint definition and use of a placebo control for the planned registrational study.
SEC filing
The company presented late-breaking Phase 2 CAD-1005 data at ISTH and said cash on hand should fund operations into early 2027.
SEC filing
The agreement, dated July 9, 2026, is not yet effective under its own terms pending a seven-day revocation window.
SEC filing (2)
The company reported gross proceeds of $8,843,849 fully sold in a Regulation D offering that began June 30, 2026, according to a filing signed July 15, 2026.
SEC filing